Search This Blog

Wednesday, March 11, 2026

60 Degrees tafenoquine regimen cured all 3 immunosuppressed relapsing babesiosis patients

 

 in expanded access trial

  • Result reinforces prior data suggesting a near-100% cure rate for tafenoquine-based regimens in relapsing babesiosis.
  • Findings prompt 60 Degrees Pharmaceuticals to call for updated treatment guidelines for managing relapsing babesiosis.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)